

NDA 208194/S-024

SUPPLEMENT APPROVAL

Eagle Pharmaceuticals, Inc. Attention: Kushal Desai Associate Director, Regulatory Affairs 50 Tice Boulevard Suite 315 Woodcliff Lake, NJ 07677

Dear Kushal Desai:

Please refer to your supplemental new drug application (sNDA) dated April 21, 2021, received April 21, 2021, and your amendments, submitted pursuant to section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Bendeka (bendamustine hydrochloride) injection.

This Prior Approval sNDA provides for revisions to reflect the language in the United States Prescribing Information (USPI) of the listed drug (LD) adding Progressive Multifocal Leukoencephalopathy (PML) as a new Warning, under Section 5.3, risk of non-melanoma skin cancer (NMSC) to Section 5.8, Other Malignancies, and updating the final concentration range in Section 2.3, Preparation for Intraveous Administration.

APPROVAL & LABELING

We have completed our review of this application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling.

WAIVER OF 1/2 PAGE LENGTH REQUIREMENT FOR HIGHLIGHTS

Please note that we have previously granted a waiver of the requirements of 21 CFR 201.57(d)(8) regarding the length of Highlights of Prescribing Information.



CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(I)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at FDA.gov.¹ Content of labeling must be identical to the enclosed labeling (text for the Prescribing Information), with the addition of any labeling changes in pending "Changes Being Effected" (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eList may be found in the guidance for industry SPL Standard for Content of Labeling Technical Qs and As.²

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that include labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(I)(1)(i)] in Microsoft Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes. To facilitate review of your submission(s), provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

REQUIRED PEDIATRIC ASSESSMENTS


Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients (which includes new salts and new fixed combinations), new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication in pediatric patients unless this requirement is waived, deferred, or inapplicable.

Because none of these criteria apply to your application, you are exempt from this requirement.

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

² We update guidances periodically. For the most recent version of a guidance, check the FDA Guidance Documents Database https://www.fda.gov/RegulatoryInformation/Guidances/default.htm.





¹ http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm

NDA 208194/S-024 Page 3

If you have any questions, call Laura Wall, Senior Regulatory Project Manager, at 301-796-2237.

Sincerely,

{See appended electronic signature page}

Nicole Gormley, MD Director Division of Hematologic Malignancies II Office of Oncologic Diseases Center for Drug Evaluation and Research

ENCLOSURE:

- · Content of Labeling
 - o Prescribing Information

This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.

/s/

NICOLE J GORMLEY 10/14/2021 12:44:56 PM

